NEW YORK (GenomeWeb News) – Agilent Technologies announced today that it has acquired the nucleic acid medicines business of Dowpharma for an undisclosed sum.
 
The acquisition is concurrent with an expansion of its nucleic acid active pharmaceutical ingredient manufacturing facility in Boulder, Colo. Agilent said that it would add large-scale nucleic acid synthesis, purification, and drying capacity to its capabilities by the end of this year.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.